VOLUME 24 - ISSUE 5

OCTOBER 2019 ISSN: 1092-8529

cambridge.org/cns

EDITOR-IN-CHIEF: STEPHEN M. STAHL





Stahl's Illustrated

Complete your collection at cambridge.org/stahlsillustrated





CNS SPECTRUMS

CONTENTS

BRAINSTORMS Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity Stephen M. Stahl	461	Examining the validity of the ADHD concept in adults and older adults Brandy L. Callahan and André Plamondon Duration of untreated illness in a cross-diagnostic sample of obsessive-compulsive disorder, panic disorder, and social anxiety disorder	518
EDITORIAL Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis" and implications for drug discovery and development Roger S. McIntyre, Carola Rong, Rodrigo B. Mansur and Elisa Brietzke LETTER TO THE EDITOR Commentary on: drug-drug interactions and clinical considerations with co-administration of antiretrovirals	467	 Paula Vigne, Pedro Fortes, Rafaela V. Dias, Luana D. Laurito, Carla P. Loureiro, Gabriela B. de Menezes, Ulrich Stangier and Leonardo F. Fontenelle Neuroanatomical features and its usefulness in classification of patients with PANDAS Brenda Cabrera, César Romero-Rebollar, Luis Jiménez-Ángeles, Alma D. Genis-Mendoza, Julio Flores, Nuria Lanzagorta, María Arroyo, 	526
and psychotropic drugs Daniel Hernandez-Huerta	470	Camilo de la Fuente-Sandoval, Daniel Santana, Verónica Medina-Bañuelos, Emilio Sacristán and Humberto Nicolini	533
CASE-BASED REVIEW ARTICLE Do cognitive and neuropsychological functioning deficits coincide with hippocampal alteration during first-psychotic episode? Bashkim Kadriu, Wen Gu, Panagiota Korenis and Jeffrey M Levine	472	Altered brain functional networks in Internet gaming disorder: independent component and graph theoretical analysis under a probability discounting task Ziliang Wang, Xiaoyue Liu, Yanbo Hu, Hui Zheng, Xiaoxia Du and Guangheng Dong	544
REVIEW ARTICLE Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder Marco Solmi, Michele Fornaro, Kuniyoshi Toyoshima, Andrè F. Carvalho, Cristiano A. Köhler, Nicola Veronese, Brendon Stubbs, Andrea de Bartolomeis and Christoph U. Correll	479	 Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment Ira D. Glick, Daisy Zamora, Danielle Kamis and John M. Davis Aggressiveness and violence in psychiatric patients: a clinical or social paradigm? Massimo C. Mauri, Giovanna Cirnigliaro, Chiara Di Pace, 	557
ORIGINAL RESEARCH Safety, tolerability, and efficacy of desvenlafaxine in children and adolescents with major depressive disorder: results from two open-label extension trials Sarah Atkinson, Louise Thurman, Sara Ramaker, Gina Buckley, Sarah Ruta Jones, Richard England and Dalia Wajsbrot	496	Silvia Paletta, Alessandra Reggiori, Carlo A. Altamura and Bernardo Dell'Osso CORRIGENDUM Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus Kevin J. Black, Henry Nasrallah, Stuart Isaacson,	564
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study Christoph U. Correll, Lily Shi, Catherine Weiss, Mary Hobart, Anna Eramo, Ruth A. Duffy, Emmanuelle Weiller and Ross A. Baker	507	Mark Stacy, Rajesh Pahwa, Charles H. Adler, Gustavo Alva, Jeffrey W. Cooney, Daniel Kremens, Matthew A. Menza, Johnathan M. Meyer, Ashwin A. Patkar, Tanya Simuni, Debbi A. Morrissette and Stephen M. Stahl	574

Editor-in-Chief

Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA; Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors

Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA Stefano Pallanti, University of Florence, Italy Donatella Marazziti, University of Pisa, Italy Thomas E. Schlaepfer, University Hospital Bonn, Germany Frank I. Tarazi, Harvard Medical School, USA Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor

Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

Editorial Board

Leslie Citrome, New York Medical College, USA Christoph U. Correll, Hofstra Northwell School of Medicine, USA Maria Conceição do Rosario, University of São Paulo Medical School, Brazil Jeffrey L. Cummings, Cleveland Clinic, USA Thilo Deckersbach, Harvard Medical School, USA Bernardo Dell'Osso, University of Milan, Italy Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium Karen D. Ersche, University of Cambridge, UK Nesrin Dilbaz, Üsküdar University NP Brain Hospital, İstanbul Gianni Faedda, The Mood Disorders Center of New York, USA Robert L. Findling, The Johns Hopkins Hospital, USA Patrick R. Finley, University of California, San Francisco, USA Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece Mark S. George, Medical University of South Carolina, USA Ira D. Glick, Stanford University, USA Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA Jon Grant, University of Chicago, USA Gregor Hasler, University of Berne, Switzerland Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA Daphne Holt, Harvard Medical School, USA Oliver Howes, King's College, London, UK Peter B. Jones, University of Cambridge, UK Andres M. Kanner, University of Miami, USA Antony D. Loebel, New York University School of Medicine, USA Donatella Marazziti, University of Pisa, Italy Roger McIntyre, University of Toronto, Canada Herbert Y. Meltzer, Northwestern University, USA Philip Mitchell, University of New South Wales, Australia Mary Moller, Pacific Lutheran University and Northwest Integrated Health, USA Mark Muse, Muse Psychological Associates, USA Humberto Nicolini, National Institutes of Health, Minister of Health, México Andrew A. Nierenberg, Harvard Medical School, USA Stefano Pallanti, University of Florence, Italy Katharine A. Phillips, Weill Cornell Medical College, USA Diego A. Pizzagalli, Harvard Medical School, USA Mark H. Pollack, Rush University Medical Center, USA Mark H. Rapaport, Emory University, USA Irismar Reis de Oliveira, Universidade Federal da Bahia, Brazil Trevor W. Robbins, University of Cambridge, UK Peter P. Roy-Byrne, University of Washington School of Medicine, USA Barbara J. Sahakian, University of Cambridge, UK Gerard Sanacora, Yale University School of Medicine, USA Alan F. Schatzberg, Stanford University School of Medicine, USA Thomas E. Schlaepfer, University of Bonn, Germany Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA Erich Seifritz, University of Zürich, Switzerland Jordan W. Smoller, Harvard Medical School, USA Dan J. Stein, University of Cape Town (UCT), South Africa Stephen Strakowski, University of Texas at Austin, USA T. Scott Stroup, Columbia University, USA Frank I. Tarazi, Harvard Medical School, USA Michael E. Thase, University of Pennsylvania, USA Michael Trimble, National Hospital for Neurology, Queen Square, London Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA Hiroyuki Uchida, Keio University School of Medicine, Japan Susan Velasquez, California Department of State Hospitals, USA Benedetto Vitiello, University of Turin, Italy Karen Dineen Wagner, The University of Texas Medical Branch, USA Katherine D. Warburton, California Department of State Hospitals, USA Stephen R. Wisniewski, University of Pittsburgh, USA Carlos A. Zarate, Jr., National Institute of Mental Health, USA Joseph Zohar, Tel Aviv University, Israel

Managing Editor

Lisa Arrington, Cambridge University Press (larrington@cambridge.org)

Aims and Scope

CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to CNS Spectrums should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated CNS Spectrums ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: *Reviews*—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; *Perspectives*—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. *Meta-guidelines*—A meta-guideline is a "guideline of guidelines" put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; *Original Research*—Reports the results of a clinical study and contains original research; the journal will also include *Brainstorms* and *Editorials* that shall be commissioned or written by the Editor-in-Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

CNS Spectrums is indexed by Index Medicus/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £546/\$866; Institutional electronic only: £415/\$663.

© Cambridge University Press 2019. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/ permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking "Request Permissions" within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster

Send address changes in the U.S.A., Canada, and Mexico to CNS Spectrums, Cambridge University Press, Journals Dept., One Liberty Plaza, 20th Floor, New York, NY 10006, U.S.A. Send address changes elsewhere to CNS Spectrums, Cambridge University Press, University Printing House, Shaftesbury Road, Cambridge CB2 8BS, England.

Online availability

CNS Spectrums is hosted on the Cambridge Core service at cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to USReprints@cambridge.org. Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: mjmrvica@mrvica.com.